Application of grouping and read-across for the evaluation of parabens of different chain lengths with a particular focus on endocrine properties

• Published in: Archives of toxicology 2021-03, Vol.95 (3), p.853-881
• Main Authors: Fayyaz, Susann, Kreiling, Reinhard, Sauer, Ursula G.
• Format: Article
• Language: English
• Subjects: Androgens; Biocompatibility; Biomedical and Life Sciences; Biomedicine; Body weight; Chemicals; Datasets; Disruption; Endocrine disruptors; Environmental Health; Estrogens; Food; In vivo methods and tests; Laboratories; Legislation; Metabolism; Occupational Medicine/Industrial Medicine; p-Hydroxybenzoic acid; Pharmacology/Toxicology; Propyl paraben; Publishing; Regulatory Toxicology; Similarity; Toxicity; Toxicology
• ISSN: 0340-5761; 1432-0738
• DOI: 10.1007/s00204-020-02967-0

This article presents the outcomes of higher-tier repeated-dose toxicity studies and developmental and reproductive toxicity (DART) studies using Wistar rats requested for methyl paraben and propyl paraben under the European Union chemicals legislation. All studies revealed no-observed adverse effects (NOAELs) at 1000 mg/kg body weight/day. These findings (absence of effects) were then used to interpolate the hazard profile for ethyl paraben, further considering available data for butyl paraben. The underlying read-across hypothesis (all shorter-chained linear n -alkyl parabens are a ‘category’ based on very high structural similarity and are transformed to a common compound) was confirmed by similarity calculations and comparative in vivo toxicokinetics screening studies for methyl paraben, ethyl paraben, propyl paraben and butyl paraben. All four parabens were rapidly taken up systemically following oral gavage administration to rats, metabolised to p -hydroxybenzoic acid, and rapidly eliminated (parabens within one hour; p -hydroxybenzoic acid within 4–8 h). Accordingly, for ethyl paraben, the NOAELs for repeated-dose toxicity and DART were interpolated to be 1000 mg/kg body weight/day. Finally, all evidence was evaluated to address concerns expressed in the literature that parabens might be endocrine disruptors. This evaluation showed that the higher-tier studies do not provide any indication for any endocrine disrupting property. This is the first time that a comprehensive dataset from higher-tier in vivo studies following internationally agreed test protocols has become available for shorter-chained linear n -alkyl parabens. Consistently, the dataset shows that these parabens are devoid of repeated-dose toxicity and do not possess any DART or endocrine disrupting properties.